^
Association details:
| Biomarker: | ER negative |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
228P - Pathologic response to neoadjuvant antiher2 therapy in HER2 equivocal overexpression with FISH amplification
Published date:
09/14/2020
Excerpt:
A serie of 71 early or locally advanced breast cancer patients with HER2 equivocal overexpression and FISH amplification who received neoadjuvant treatment with chemotherapy and antiHER2 drugs...The pCR in ER negative was 52% and the subgroup with a ratio of HER2/CEP17 superior to 2.0 was the more responsive with a total of 80% pCR compared with 25% in the ratio inferior to 2.0....However, the subgroup with ER negative and high expression of HER2 / CEP17 ratio achieves a percentage of pCR that reaches up to 80%.
